NEW YORK – Following the termination of its agreement with Exact Sciences subsidiary Genomic Health, Biocartis plans to further invest in current collaborations and future projects with firms to develop in vitro diagnostic (IVD) tests for multiple cancer types and infectious diseases.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.